Optum Frontier Therapies II operates as a 3PL with FDA registration and an extensive licensing footprint covering 49 states, though one license has lapsed. While the company maintains clean regulatory records with no FDA recalls or warning letters and demonstrates strong DSCSA compliance, it lacks NABP accreditation and DEA registration, which may limit its ability to handle controlled substances in the cold chain.